OptimizeRx Corporation (OPRX)
| Market Cap | 149.75M -54.0% |
| Revenue (ttm) | 98.65M -5.8% |
| Net Income | 4.60M |
| EPS | 0.25 |
| Shares Out | 18.84M |
| PE Ratio | 32.31 |
| Forward PE | 8.46 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 271,582 |
| Open | 7.83 |
| Previous Close | 7.83 |
| Day's Range | 7.60 - 8.09 |
| 52-Week Range | 4.54 - 22.25 |
| Beta | 1.05 |
| Analysts | Strong Buy |
| Price Target | 12.40 (+55.98%) |
| Earnings Date | Aug 12, 2026 |
About OPRX
OptimizeRx Corporation operates as a digital healthcare technology company. It offers Dynamic Audience Activation Platform, which generates dynamic audiences with predictive analytics through machine learning methods; Micro-Neighborhood Targeting, which creates consumer audiences using a privacy-first process; Profiler, which provides insights into its customers’ target consumers; banner messages, including brand messaging, therapeutic support messaging, affordability messaging, limited distribution drug information, and patient support program... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for OPRX stock is "Strong Buy." The 12-month stock price target is $12.4, which is an increase of 55.98% from the latest price.
News
OptimizeRx reports Q2 EPS 16c, consensus 11c
Reports Q2 revenue $20.5M, consensus $20.2M. Stephen L. Silvestro, OptimizeRx (OPRX) CEO commented, “Second quarter revenue and adjusted EBITDA both exceeded consensus expectations, reflecting continu...
OptimizeRx backs FY26 revenue view $95M-$100M, consensus $97.41M
The company said, “The Company is reiterating its fiscal year 2026 guidance, and expects revenue of $95 million to $100 million and adjusted EBITDA of $21 million to $25 million.”…
OptimizeRx names Andy D’Silva CFO, Heather Favazza chief accounting officer
OptimizeRx (OPRX) announced the company’s board of directors has appointed Andy D’Silva to succeed Ed Stelmakh as CFO, effective January 1, 2027. The board has also appointed Heather Favazza as…
OptimizeRx price target lowered to $12 from $14 at Stifel
Stifel lowered the firm’s price target on OptimizeRx (OPRX) to $12 from $14 and keeps a Buy rating on the shares. The firm is “optimistic” an enhanced product offering combined…
OptimizeRx price target raised to $11 from $9 at Citizens
Citizens raised the firm’s price target on OptimizeRx (OPRX) to $11 from $9 and keeps an Outperform rating on the shares following the Q2 results. The stabilization of the macro…
OptimizeRx Earnings Call Transcript: Q2 2026
Q2 2026 revenue and adjusted EBITDA exceeded expectations despite a 30% year-over-year revenue decline, driven by margin expansion and operational discipline. Full-year guidance was reaffirmed, with profitability improvements expected to be sustainable and new product launches strengthening the platform.
OptimizeRx Earnings release: Q2 2026
OptimizeRx released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
OptimizeRx Quarterly report: Q2 2026
OptimizeRx has published its Q2 2026 quarterly earnings report on August 12, 2026.
OptimizeRx Announces Finance Leadership Appointments to Support the Next Phase of Growth
The Company Names Andy D'Silva as the next Chief Financial Officer and Heather Favazza as Chief Accounting Officer effective January 1, 2027
OptimizeRx Reports Second Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance
– Q2 revenue totals $20.5 million– Q2 net loss and adjusted EBITDA of $(0.7) million and $4.9 million, respectively– Reaffirms fiscal year 2026 revenue guidance of $95 - $100 million and adjusted E...
OptimizeRx Sets Second Quarter 2026 Conference Call for August 12, 2026, at 4:30 p.m. ET
WALTHAM, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engag...
OptimizeRx appoints Sarah Bast as chief marketing officer
OptimizeRx (OPRX) announced the appointment of Sarah Bast as chief marketing officer. Bast brings more than two decades of pharmaceutical marketing experience to the leadership team, including experti...
OptimizeRx Appoints Veteran Point of Care Marketing Leader Sarah Bast as Chief Marketing Officer
WALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engag...
OptimizeRx Launches CopayCue™, a Next-Generation Copay Activation Solution Powered by Real-Time Prescribing Intent
Enhanced technology delivers brand savings offers directly within the prescribing workflow, when HCP intent is highest Enhanced technology delivers brand savings offers directly within the prescribing...
OptimizeRx Slides: Corporate presentation
OptimizeRx has posted slides in relation to its latest quarterly earnings report, which was published on June 30, 2026.
OptimizeRx Launches Natural Language Audience Builder for Life Sciences DSPs and Agency Media Planning Platforms
Patent-pending, embeddable NLAB technology enables pharma and agency marketers to build custom, verified HCP audiences using natural-language prompts Patent-pending, embeddable NLAB technology enables...
OptimizeRx Transcript: AGM 2026
The meeting covered director elections, executive compensation, equity plan amendments, and auditor ratification. All directors were elected, executive compensation and increased equity plan shares were approved, but the evergreen provision was not. Auditor ratification passed.
OptimizeRx Transcript: 46th Annual William Blair Growth Stock Conference
A scalable, AI-driven point-of-care platform is expanding its reach in the pharma industry, delivering industry-leading ROI and script lift through deep EHR integration and patented technology. Growth is accelerating via DSP partnerships, with strong financials and a significant market opportunity ahead.
OptimizeRx Proxy statement: Proxy filing
OptimizeRx filed a proxy statement on June 1, 2026, providing details for shareholder voting and corporate governance matters.
OptimizeRx to Participate in Upcoming Investor Conferences
WALTHAM, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare solutions helping life sciences companies reach and engage healthcar...
DeepIntent Becomes First Healthcare DSP to Integrate OptimizeRx's Authenticated EHR Network
Powered by OptimizeRx's new programmatic infrastructure, collaboration expands access to premium point of care inventory for life sciences marketers Powered by OptimizeRx's new programmatic infrastruc...
OptimizeRx price target lowered to $11 from $20 at Lake Street
Lake Street lowered the firm’s price target on OptimizeRx (OPRX) to $11 from $20 and keeps a Buy rating on the shares. While “disappointed” with the company’s lowered revenue guidance,…
OptimizeRx price target lowered to $10 from $11 at B. Riley
B. Riley lowered the firm’s price target on OptimizeRx (OPRX) to $10 from $11 and keeps a Buy rating on the shares. The underlying drivers of the second consecutive guidance…
OptimizeRx price target lowered to $7 from $10 at Stephens
Stephens lowered the firm’s price target on OptimizeRx (OPRX) to $7 from $10 and keeps an Equal Weight rating on the shares. OptimizeRx reduced revenue guidance by 13% based on…
OptimizeRx price target lowered to $14 from $17 at Stifel
Stifel lowered the firm’s price target on OptimizeRx (OPRX) to $14 from $17 and keeps a Buy rating on the shares.